Get the Stockscreener App
28.56
12.22%
3.11
After Hours:
27.86
-0.70
-2.45%
Vyne Therapeutics Inc stock is traded at $28.56, with a volume of 93,256.
It is up +12.22% in the last 24 hours and down -11.89% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$25.45
Open:
$25.5
24h Volume:
93,256
Relative Volume:
6.01
Market Cap:
$19.07M
Revenue:
$454.00K
Net Income/Loss:
$-21.72M
P/E Ratio:
-53.51
EPS:
-0.5337
Net Cash Flow:
$-25.74M
1W Performance:
-29.29%
1M Performance:
-11.89%
6M Performance:
+0.21%
1Y Performance:
-60.88%
1-Day Range:
$23.37
$28.56
1-Week Range:
$23.37
$46.95
52-Week Range:
$14.03
$79.75
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
28.56 | 339.86K | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Business Wire
VYNE|Vyne Therapeutics Inc|Price:0.509|Chg%:-0.012 - TradingKey
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Vyne Therapeutics Provides Update Regarding C - Moomoo
Form 4 Vyne Therapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
VYNE Therapeutics (Ticker: VYNE) CFO reports tax-share withholding event - Stock Titan
Tax withholding trims stake of VYNE Therapeutics Inc. (VYNE) CSO - Stock Titan
VYNE Therapeutics (VYNE) CLO has shares withheld for RSU taxes - Stock Titan
VYNE Therapeutics Inc. Revenue Breakdown – NASDAQ:VYNE - TradingView
Vyne Therapeutics Inc (VYNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - marketscreener.com
Press Release: VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger With Yarrow Bioscience - Moomoo
VYNE Therapeutics To Go Ex-Dividend On July 24th, 2026 With 0.40242 USD Special Dividend Per Share - Moomoo
Vyne Therapeutics set for 1-for-50 reverse stock split on July 24 - Bitget
VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update - Kalkine Media
Vyne Therapeutics Announces Aggregate Cash Div of $17.3M, or Abput $0.40242 Per Shr >VYNE - Moomoo
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - Minichart
VYNE Therapeutics approves 1-for-50 reverse stock split - Investing.com
VYNE Therapeutics approves 1-for-50 reverse stock split By Investing.com - Investing.com Australia
VYNE Therapeutics approves 1-for-50 reverse stock split ahead of Yarrow merger - MSN
VYNE Therapeutics Announces Reverse Split and Merger Plans - TipRanks
VYNE Therapeutics announces 1-for-50 reverse stock split - TipRanks
VYNE Announces 1-for-50 Reverse Stock Split, $17.3M Special Cash Dividend Ahead of Yarrow Merger - TradingView
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - marketscreener.com
Press Release: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection With the Proposed Merger With Yarrow Bioscience - Moomoo
VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger - Stock Titan
VYNE Therapeutics Inc. Announces Merger with Yarrow Bioscience and Key Corporate Updates – SEC Form 8-K Filing July 2026 – Minichart - Minichart
VYNE Special Dividend Tied To Merger: My Take On The 8-K Learn (V8sbUVk4ib) - Mshale
Vyne Therapeutics holds shareholder special meeting on merger proposals - Bitget
VYNE Therapeutics (VYNE) investor reports 5.5M-share, 16.5% ownership stake - Stock Titan
VYNE Therapeutics (NASDAQ: VYNE) investors approve Yarrow merger - Stock Titan
Vyne Therapeutics Inc (NASDAQ: VYNE) Share Price, VYNE Stock News, VYNE Share Price & Updates - Kalkine
VYNE Therapeutics advances reverse merger with Yarrow Bioscience - TipRanks
VYNE Therapeutics Inc. (VYNE) reports 13.8% stake by Zhang Xiaofan - Stock Titan
VYNE Therapeutics (NASDAQ: VYNE) shares Yarrow transaction deck - Stock Titan
VYNE Therapeutics (NASDAQ: VYNE) outlines Yarrow merger, dividend terms - Stock Titan
Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VYNE Therapeutics (VYNE) Announces Special Dividend of $0.38 Ami - GuruFocus
VYNE Therapeutics Announces Special Cash Dividend in Connection With Pending Merger With Yarrow Bioscience - Moomoo
Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend? - Kalkine Media
Vyne Therapeutics Declares Special Cash Divid - Moomoo
VYNE Announces Special Cash Dividend Ahead of Merger - GuruFocus
VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026 - marketscreener.com
VYNE Therapeutics declares $16.5M dividend ahead of merger - Investing.com
VYNE Therapeutics Announces $16.5M Special Cash Dividend Ahead of Merger with Yarrow Bioscience - Minichart
VYNE Therapeutics declares $16.5M dividend ahead of merger By Investing.com - Investing.com Nigeria
VYNE declares special dividend ahead of Yarrow merger - TipRanks
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience - The Manila Times
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):